PDGFRB and obstructive sleep apnea syndrome: Drawing conclusions from the reviewed data in humans and companion animals, combinations should eventually be considered for the treatment of OSA (including EGFR or PDGFR targeting), HNSCC (with c-Kit inhibition), and mammary carcinoma (using multi-TKIs).